文献速递胃肠动力与功能性疾病

随机临床试验:粪菌移植治疗腹泻型肠易激综合征

Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea.
PubMed 文献 · Aliment Pharmacol Ther · 2023-09-05

该随机试验将56例腹泻型肠易激综合征患者按1:1分配至十二指肠途径粪菌移植组或安慰剂组,在基线和第4周给药。第12周时,粪菌移植组57.1%与安慰剂组46.4%达到主要终点(IBS-SSS评分下降超过50分),差异无统计学意义(p=0.42);粪菌移植组腹胀改善率72%高于安慰剂组30%(p=0.005)。

要点

  • 第12周主要终点达标率粪菌移植组57.1% vs 安慰剂组46.4%(p=0.42),无显著差异。
  • 腹胀改善率粪菌移植组72% vs 安慰剂组30%(p=0.005)。
  • 开放标签扩展期65.2%达到主要终点、82.4%腹胀改善。

核心结论

  • 间隔四周进行两次粪菌移植未显著降低IBS-SSS评分,但更多患者腹胀改善,且与产硫化氢细菌减少相关。

研究设计与样本

  • 随机试验,56例腹泻型肠易激综合征患者按1:1随机分配至粪菌移植组或安慰剂组,经十二指肠途径在基线和第4周给药。
  • 主要终点为第12周IBS严重度评分系统(IBS-SSS)评分下降超过50分;次要终点为第12周腹胀改善和肠道菌群变化。
  • 12周随访后,安慰剂组患者接受开放标签粪菌移植。

主要发现

  • 第12周达到主要终点者粪菌移植组57.1% vs 安慰剂组46.4%(p=0.42)。
  • 腹胀改善者粪菌移植组72% vs 安慰剂组30%(p=0.005)。
  • 开放标签扩展期65.2%达到主要终点、82.4%腹胀改善。
  • 粪菌移植组第12周粪便微生物中Ruminococcus gnavus等细菌减少、Lawsonibacter等细菌富集,安慰剂组无变化。
  • 功能分析显示粪菌移植患者产硫化氢途径下降(p<0.05),伴随贡献细菌减少;无与粪菌移植相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Faecal microbiota transplantation (FMT) has been shown to improve symptoms in a proportion of patients with irritable bowel syndrome (IBS). AIM: We performed a randomised trial to assess the efficacy of FMT in patients with IBS. METHODS: We randomised 56 patients with diarrhoea-predominant IBS 1:1 to FMT or placebo via the duodenal route at baseline and week 4. The primary outcome was > 50 points decrease in IBS severity scoring system (IBS-SSS) score at week 12. Secondary outcomes were improvement in bloating and change in gut microbiota at week 12. After 12-week follow-up, those in the placebo group were assigned to receive open-label FMT. RESULTS: At week 12, 57.1% in the FMT group and 46.4% in the placebo group achieved the primary endpoint (p = 0.42). More patients receiving FMT than placebo had improvement in bloating (72% vs 30%; p = 0.005). In an open-label extension, 65.2% and 82.4% of patients achieved, respectively, the primary endpoint and improvement in bloating. Faecal microbiome of patients in the FMT group showed a reduction in bacteria like Ruminococcus gnavus and enrichment of bacteria such as Lawsonibacter at week 12, while no change in the placebo group. Functional analyses showed that the hydrogen sulphide-producing pathway decreased in patients who had FMT (p < 0.05) accompanied by a reduction in contributing bacteria. There were no serious adverse events related to FMT. CONCLUSION: FMT performed twice at an interval of four weeks did not significantly reduce IBS-SSS score. However, more patients had improvement in abdominal bloating, which was associated with a reduction in hydrogen sulphide-producing bacteria. (ClinicalTrials.gov NCT03125564).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yau YK, Su Q, Xu Z, et al. Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2023. PMID: 37667968. doi:10.1111/apt.17703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。